Trial met primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenibImfinzi monotherapy met the overall survival endpoint of non-inferiority vs. sorafenib

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 15 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 October 2021 06:11:08 UTC.